SCHEMBL5649673

SCHEMBL5649673

CC(C)CCNS(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
HTT P42858 2/20 0.56
ALDH1A1 P00352 7/20 0.54
NAMPT P43490 3/20 0.52
CA12 O43570 3/20 0.49
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA9 Q16790 3/20 0.49
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
ADAMTS4 O75173 1/20 0.44
PKM P14618 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20327817 0.84 ALDH1A1 (0.62) KMT2AHTTALDH1A1CA12CA2
SCHEMBL27896976 0.83 HTT (0.72) KMT2AHTTALDH1A1CA12CA1
SCHEMBL3153289 0.83 SIGMAR1 (0.59) KMT2AHTTALDH1A1NAMPTCA12
SCHEMBL26787768 0.83 ALDH1A1 (0.64) KMT2AHTTALDH1A1CA12CA1
SCHEMBL3704958 0.83 CA12 (0.71) KMT2AHTTALDH1A1NAMPTCA12
SCHEMBL6568086 0.82 ALDH1A1 (0.61) KMT2AHTTALDH1A1NAMPTSMN1; SMN2
SCHEMBL28023600 0.82 ALDH1A1 (0.67) KMT2AALDH1A1CA12CA1CA2
SCHEMBL16964854 0.82 CA1 (0.64) KMT2AHTTALDH1A1NAMPTCA12
SCHEMBL13766688 0.82 MEP1B (0.60) KMT2AHTTALDH1A1NAMPTCA1
SCHEMBL28719400 0.80 MMP2 (0.56) KMT2AHTTALDH1A1NAMPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KMT2A 4150/4885HTT 3259/4885ALDH1A1 1304/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KMT2A 4322/4885HTT 3391/4885ALDH1A1 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.